Citius Oncology Inc (CTOR)

개요 뉴스 가격 이력 토론 예측

Relative Volume:

Citius Oncology Inc Stock (CTOR) Company Profile

Citius Oncology Inc

Healthcare (1131)

(908) 967-6677

11 COMMERCE DRIVE, CRANFORD

최신 SEC 제출 서류

CTOR's Discussions on Twitter

CTOR을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
CTOR Citius Oncology Inc	1.03	84.80M	0	0	0	0.00
ZTS Zoetis Inc	125.14	55.45B	9.40B	2.65B	2.24B	5.935
TAK Takeda Pharmaceutical Co Adr	15.59	49.25B	29.63B	260.53M	5.51B	0.0788
HLN Haleon Plc Adr	10.00	45.02B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	30.74	35.81B	16.88B	666.71M	251.19M	0.6132
UTHR United Therapeutics Corp	491.62	20.98B	3.08B	1.24B	1.07B	25.61

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-09-23	업그레이드	Maxim Group	Hold → Buy
2024-11-27	개시	Maxim Group	Buy

Citius Oncology Inc 주식(CTOR)의 최신 뉴스

Citius Oncology Inc (CTOR) 재무 분석

Citius Oncology Inc (CTOR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

Citius Oncology Inc (CTOR)

Citius Oncology Inc Stock (CTOR) Company Profile

CTOR을(를) 다른 주식과 비교

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Citius Oncology Inc 주식(CTOR)의 최신 뉴스

Earnings Miss: Will Citius Oncology Inc stock sustain high P E ratiosJuly 2025 Institutional & Verified Technical Signals - moha.gov.vn

Citius Oncology, Inc. (NASDAQ:CTOR) Sees Significant Increase in Short Interest - Defense World

Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update - MarketBeat

Citius Oncology (CTOR) Stock Analysis Report | Financials & Insights - Benzinga France

Citius Oncology’s LYMPHIR FDA Win Clouded by High Upfront Costs, Regulatory Risks, and Uncertain Market Adoption - TipRanks

Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why - Benzinga

Citius Oncology, Inc. Full Year Loss Increases - Nasdaq

Citius Oncology Transitions to Commercial Stage: Analyzing the 10-K Filing and the 2026 Outlook for LYMPHIR - FinancialContent

Citius Oncology (NASDAQ:CTOR) Issues Quarterly Earnings Results - MarketBeat

Citius Oncology Fiscal 2025 Loss Widens - marketscreener.com

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - WV News

Citius Pharmaceuticals, Inc. SEC 10-K Report - TradingView — Track All Markets

Citius Oncology, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025 - marketscreener.com

Citius Oncology raises $18M through direct offering - MSN

Citius Oncology : Amendment to Statement of Changes in Beneficial Ownership (Form 4/A) - marketscreener.com

Is Citius Oncology Inc a good long term investmentFibonacci Extensions & Free Superior Trading Gains - earlytimes.in

Citius Oncology Earnings Notes - Trefis

Citius Oncology, Inc.(NasdaqCM: CTOR) added to Russell 3000E Value Index - marketscreener.com

Citius Oncology (CTOR) Price Target Increased by 100.00% to 6.12 - MSN

Citius Oncology closes $18 million in offerings to support LYMPHIR launch - Investing.com Nigeria

Citius Oncology Raises $18M Through Direct Offering - TipRanks

Citius Oncology Announces Closing of $18 Million Concurrent Regi - GuruFocus

Citius Oncology closes $18 million in offerings to support LYMPHIR launch By Investing.com - Investing.com South Africa

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Barchart.com

Citius Oncology (NASDAQ:CTOR) Shares Up 6.4%What's Next? - MarketBeat

Citius Oncology raises $18 million to support cancer therapy launch By Investing.com - Investing.com Canada

Citius Oncology, Inc. announced that it has received $16.6 million in funding - marketscreener.com

Citius Oncology (NASDAQ: CTOR) raises $1.4M, adds large warrant package - Stock Titan

Citius Oncology added to the Russell Microcap Index - MSN

Citius Oncology shares sink after announcing $18M fundraising deal - MSN

Citius Oncology raises $18 million to support cancer therapy launch - Investing.com

Citius Oncology stock tumbles after $18M capital raise By Investing.com - Investing.com Nigeria

Citius Oncology stock tumbles after $18M capital raise - Investing.com India

Citius Oncology announces $18 million concurrent registered direct offering and private placement priced at-the-market under Nasdaq rules - marketscreener.com

Press Release: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - 富途牛牛

Citius Oncology, Inc. announced that it expects to receive $16.6 million in funding - marketscreener.com

What drives Citius Oncology Inc stock priceStock Price Divergence & Calculate Profit Targets With AI Accuracy - earlytimes.in

Citius Oncology Launches Lymphir In US For Skin Cancer - MSN

Citius Oncology expands lymphir distribution to Turkey, Middle East By Investing.com - Investing.com Nigeria

Is Citius Oncology Inc. stock a top pick in earnings season2025 Dividend Review & Weekly Top Gainers Alerts - Newser

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim - The Malaysian Reserve

Citius Oncology expands lymphir distribution to Turkey, Middle East - Investing.com India

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Midd - GuruFocus

Citius Oncology expands Lymphir distribution to Turkey and Middle East countries - marketscreener.com

Citius Oncology Expands Lymphir Distribution To Turkey And Middle East Countries - TradingView — Track All Markets

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim – Company AnnouncementFT.com - Financial Times

What Wall Street predicts for Citius Oncology Inc. stock priceStop Loss & Growth Focused Stock Pick Reports - Newser

Citius Oncology Inc (CTOR) 재무 분석

매출

순이익

현금흐름

주당 순 이익

CTOR과 유사한 종목